Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03415126 · ClinicalTrials.gov registry record · Phase 1
A Study of ASN007 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Asana BioSciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT03415126: Completed Phase 1 study, sponsored by Asana BioSciences.
NCT03415126 is a Phase 1 study that has completed, run by Asana BioSciences. The registered enrollment target is 49 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03415126, a Phase 1 study, has completed, sponsored by Asana BioSciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.
Primary Outcome
The MTD will be determined by evaluating the number of subjects with treatment related dose limiting toxicity. This is the primary endpoint of Part A
Interventions
- DRUG ASN007: ascending doses
- DRUG ASN007 RD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-01-19 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 1 |
What the finished NCT03415126 record still lists
NCT03415126 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower).
The record links to 0 conditions, and to 2 interventions - of which ASN007: ascending doses is the first listed.
NCT03415126 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03415126 about?
NCT03415126 is a clinical study titled "A Study of ASN007 in Patients With Advanced Solid Tumors". The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.
What is the current status of trial NCT03415126?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2018-01-19. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03415126?
The interventions under investigation include: ASN007: ascending doses (DRUG), ASN007 RD (DRUG).
Who is sponsoring clinical trial NCT03415126?
This trial is sponsored by Asana BioSciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03415126's enrollment target sits among peer trials
49 1017th of 2000 higher than 976 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI